Literature DB >> 2140325

DOPA decarboxylase inhibition does not influence the diuretic and natriuretic response to exogenous alpha-atrial natriuretic peptide in man.

S Kageyama1, J Brown, R Causon, M O'Flynn, V Aber.   

Abstract

The role of dopamine synthesis in the renal actions of human alpha-atrial natriuretic peptide (alpha ANP) was investigated in six dehydrated volunteers using the DOPA decarboxylase inhibitor carbidopa. Each subject received oral placebo or carbidopa (100 mg) followed by an infusion of alpha ANP 10 pmol.kg-1.min-1 for 1 h. The responses to placebo alone and to carbidopa alone were investigated on separate occasions. alpha ANP produced a similar increase in plasma immunoreactive alpha ANP whether placebo or carbidopa pretreatment had been given. Urinary dopamine excretion was increased by alpha ANP. Carbidopa pretreatment substantially attenuated this increase without affecting the natriuretic or water-diuretic response to alpha ANP. Carbidopa also failed to alter the change in filtration fraction produced by alpha ANP. The results suggest that increased synthesis of intrarenal dopamine is not required for the renal effects of alpha ANP in man.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140325     DOI: 10.1007/bf00315020

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  The effect of intravenous frusemide on urine dopamine in normal volunteers: studies with indomethacin and carbidopa.

Authors:  R F Jeffrey; T M Macdonald; M Rutter; S Freestone; J Brown; R R Samson; M R Lee
Journal:  Clin Sci (Lond)       Date:  1987-08       Impact factor: 6.124

2.  Blockade of renal effects of dopamine in the dog by the DA1 antagonist SCH 23390.

Authors:  E D Frederickson; T Bradley; L I Goldberg
Journal:  Am J Physiol       Date:  1985-08

3.  Novel double-isotope technique for enzymatic assay of catecholamines, permitting high precision, sensitivity and plasma sample capacity.

Authors:  M J Brown; D A Jenner
Journal:  Clin Sci (Lond)       Date:  1981-11       Impact factor: 6.124

4.  Blood levels and renal effects of atrial natriuretic peptide in normal man.

Authors:  P Weidmann; L Hasler; M P Gnädinger; R E Lang; D E Uehlinger; S Shaw; W Rascher; F C Reubi
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

5.  Atrial natriuretic peptide: an endogenous factor enhancing sodium excretion in man.

Authors:  J Anderson; A Struthers; N Christofides; S Bloom
Journal:  Clin Sci (Lond)       Date:  1986-04       Impact factor: 6.124

6.  Renal mechanisms of human alpha-atrial natriuretic peptide in man.

Authors:  J Brown; L Corr
Journal:  J Physiol       Date:  1987-06       Impact factor: 5.182

7.  The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride.

Authors:  S Freestone; T M MacDonald; R F Jeffrey; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

8.  Relationship between urinary dopamine production and natriuresis after acute intravascular volume expansion with sodium chloride in dogs.

Authors:  J R Sowers; P D Crane; F W Beck; M McClanahan; M E King; P K Mohanty
Journal:  Endocrinology       Date:  1984-12       Impact factor: 4.736

9.  Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man.

Authors:  R W Alexander; J R Gill; H Yamabe; W Lovenberg; H R Keiser
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Renal effects of atrial natriuretic factor are independent of dopamine1 receptors.

Authors:  M B Murphy; A S Bass; L I Goldberg
Journal:  Am J Physiol       Date:  1988-09
View more
  1 in total

1.  Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension.

Authors:  C Fronzaroli; G La Villa; G Strazzulla; M Mannelli; F Franchi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.